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Abstract: Several health benefits, associated with human milk oligosaccharides (HMOS), have been 
revealed in the last decades. Further progress, however, requires not only the establishment of a 
simple "routine" method for absolute quantification of complex HMOS mixtures but also the 
development of novel synthesis strategies to improve access to tailored HMOS. Here, we introduce 
a combination of salvage-like nucleotide sugar-producing enzyme cascades with Leloir-
glycosyltransferases in a sequential pattern for the convenient tailoring of stable isotope-labeled 
HMOS. We demonstrate the assembly of [13C6]galactose into lacto-N- and lacto-N-neo-type HMOS 
structures up to octaoses. Further, we present the enzymatic production of UDP-[15N]GlcNAc and 
its application for the enzymatic synthesis of [13C6/15N]lacto-N-neo-tetraose for the first time. An 
exemplary application was selected—analysis of tetraose in complex biological mixtures—to show 
the potential of tailored stable isotope reference standards for the mass spectrometry-based 
quantification, using matrix-assisted laser desorption/ionization-time of flight mass spectrometry 
(MALDI-TOF-MS) as a fast and straightforward method for absolute quantification of HMOS. 
Together with the newly available well-defined tailored isotopic HMOS, this can make a crucial 
contribution to prospective research aiming for a more profound understanding of HMOS 
structure-function relations. 
Keywords: glycobiology; biocatalysis; human milk oligosaccharides; isotopic labeling; 
quantification: nucleotide sugars; lacto-N-biose type; lacto-N-neo type; glycosyltransferases; 
capillary gel electrophoresis; MALDI-MS 
 
1. Introduction 
It has become increasingly apparent that human milk oligosaccharides (HMOS) consist of a 
cocktail of complex glycans and play important biological roles well beyond simple nutrition. Most 
of HMOS are involved in very complex and important biological mechanisms [1,2], protecting the 
gastrointestinal tract against toxin and viral and bacterial adhesion, mediating immune modulations 
and stimulating the brain development and several more [1–3]. HMOS are present in large quantities 
and are the third most abundant group of compounds in human milk, directly after lactose and lipids 
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[3–5]. They display a unique and extremely high structural diversity [2,3,6,7], with approximately 150 
elucidated structures so far [8]. 
Interestingly, it has been found that biological functions depend on both, the specific structure 
and the quantity of the HMOS present [8,9]. Striking is also their remarkable variability in 
composition and concentration of milk oligosaccharides (milk OS) during lactation depending on the 
donor phenotype [10]. Therefore, methods for absolute quantification of milk OS are of high interest 
and a prerequisite for the deeper understanding of the biological roles of HMOS. Moreover, a rising 
amount of HMOS is authorized as a nutrition supplement, which promotes an urgent future request 
for a rapid and robust “routine” quantification method for suitable quality control [11–13]. 
However, absolute quantification of milk OS has been proven to be a challenging task. The most 
commonly applied chromatographic, electrophoretic, and spectrometric methods often deliver only 
relative quantification of milk OS [14–16]. One reason for limited attempts to quantify diverse and 
complex milk OS is a small number of available standards. Matrix-assisted laser 
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) methods combined with 
stable isotope labeling have already been successfully applied for absolute quantification of other 
complex OS like N-glycans [17]. Nevertheless, this technique also relies on the availability of isotope-
labeled internal standards [17–19]. Improved access to tailored isotopically labeled milk OS would 
enable the application of fast and straightforward MALDI-TOF-MS-based methods for absolute 
quantification of milk OS, suitable also for a complex sample matrix-like human milk. 
Beside chemical routes for the HMOS synthesis [20,21], the enzyme-mediated HMOS tailoring 
is a very straightforward strategy [7,21–25]. Leloir-glycosyltransferases are especially known for their 
quantitative substrate conversion, a very high specificity, and high regioselectivity by utilizing 
activated nucleotide sugars [26]. Availability of recombinant enzymatic tools like a β1,4-
galactosyltransferase-1 (β4GalT) [27,28], a β1,3-N-acetylglucosaminyltransferase (β3GlcNAcT) [29–
31], and a β1,3-galactosyltransferase (β3GalT) [32,33] nowadays enables an efficient enzymatic 
synthesis approach towards linear HMOS. Elongation of lactose with N-acetyllactosamine (Gal(β1-
4)GlcNAc-, LacNAc type 2) or lacto-N-biose (Gal(β1-3)GlcNAc-, LacNAc type 1) represents a basic 
motif of linear and branched HMOS. More precisely, the LacNAc units have to be β1-3-linked for the 
correct biomimetic structure of linear HMOS while additional β1-6-linked LacNAc units form the 
backbone of branched (iso-)HMOS [1]. 
Nevertheless, the Leloir-glycosyltransferases-mediated, isotopically labeled HMOS synthesis 
depends on the availability of the isotope-labeled nucleotide sugars as uridine-5´-diphospho-α-D-
galactose (UDP-Gal) or uridine-5´-diphospho-α-D-N-acetylglucosamine (UDP-GlcNAc). Synthesis 
approaches of isotope-labeled nucleotide sugars are not mentioned very frequently in literature. An 
in vitro synthesis of 14C-enriched UDP-[14C]Gal was demonstrated already 50 years ago using an 
uridyltransferase [34]. Virgilio et al. incorporated 13C-labeled galactose by the enzymatic synthesis in 
poly-LacNAc type II tetra- and hexaoses. The synthesis principle was also demonstrated for the 
synthesis of non-labeled linear lacto-N-neo-type HMOS and therefore postulated as a possible way 
towards isotopically labeled HMOS [35]. A chemoenzymatic strategy for the synthesis of UDP-
[2H]GlcNAc starting from the sugar-1-phosphate was performed using the uridylyltransferases 
activity of the bifunctional Escherichia coli (E.coli) enzyme GlmU [36]. Recent developments of 
cascades with salvage pathway enzymes and their use in novel synthesis strategies can provide the 
nucleotide sugars UDP-Gal and UDP-GlcNAc in a much more efficient way [37–39]. Furthermore, 
recent studies impressively demonstrate the value of defined isotopically labeled OS for in vivo 
research applications [40]. 
Here, we utilize a previously described strategy in a very efficient synthesis set-up for the 
production of UDP-[15N]GlcNAc and UDP-[13C6]Gal on a 200 and a 400 µmol scales. [39]. As 
previously demonstrated, nucleotide sugars are readily accessible for Leloir-glycosyltransferases-
mediated glycan synthesis without further purification steps [32]. In this way, we demonstrate the 
synthesis of linear 13C6-labeled Lacto-N-type and Lacto-N-neo-type HMOS up to octaoses as well as 
13C6 and 15N-labeled lacto-N-neo-tetraose ([13C6/15N]LNnT), to the best of our knowledge, for the first 
time in a sequential enzymatic synthesis cascade. Production in a 125 µmol scale of [13C6/15N]LNnT 
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facilitates its application for absolute MALDI-TOF-MS-based quantification of tetraose in milk 
samples as a proof-of-concept exercise to show the potential utility of tailored stable isotope-labeled 
HMOS for quantitative studies. 
2. Results and Discussion 
2.1. Nucleotide Sugar Synthesis 
Synthesis of milk OS requires building blocks—monosaccharides. In order to be used in 
oligosaccharide synthesis mediated by Leloir-glycosyltransferases, these monosaccharides need to be 
activated first to a high-energy donor form—nucleotide sugars. Production of isotope-labeled 
nucleotide sugars was carried out as described before, employing cascades of salvage pathway 
enzymes in a repetitive batch approach (Supplementary Materials, Scheme S1) [39]. 
Briefly, within the nucleotide sugar-producing cascades, the monosaccharides (1 or 4) were first 
phosphorylated by the respective ATP-dependent kinases (N-acetylhexosamine-1-kinase from 
Bifidobacterium longum (NahK) or E.coli galactokinase (EcGalK)). The corresponding UDP-sugar 
pyrophosphorylases (UDP-GlcNAc pyrophosphorylase (AGX1) or UDP-sugar pyrophosphorylase 
from Hordeum vulgare (HvUSP)) catalyse the UTP-dependent UDP-sugar synthesis from the 
respective sugar-1-phosphates (2 or 5), and an inorganic pyrophosphatase (PPiase) hydrolyses the 
inhibiting by-product pyrophosphate (PPi) (Scheme 1). Regarding the repetitive batch synthesis 
strategy, a centrifugal concentrator was utilized to carry out the enzymatic synthesis and for the 
subsequent product separation of the respective batch. Each new cycle of the repetitive batch 
approach started with the addition of fresh substrate to the enzymes, remaining in the concentrator 
(Supplementary Materials, Scheme S1). From a commercial point of view, isotope-labeled 
monosaccharide substrates are rather precious. With this in mind, the synthesis conditions for 
compounds 3 and 6 were carefully adjusted to increase the product yield. By pre-tempering of all 
reaction solutions and elongation of the reaction time to one hour, we were able to obtain full 
substrate conversion (Table 1). Product concentrations were determined by capillary electrophoresis 
with UV detection (CE-UV) (data not shown) and the product verification was carried out via 
electrospray ionization mass spectrometry (ESI-MS) as previously reported (Table 1; Supplementary 
Materials, Figures MS1, and MS2) [32,37,39]. The non-labeled nucleotide sugars utilized in this study 
were available from our earlier work [39] (Supplementary Materials, Figures MS3, and MS4). The 
synthesized compound 6 (UDP-[13C6]Gal) contains isotopically enriched galactose with a stable 13C 
incorporated at each carbon position of the hexose which causes the mentioned mass difference of 6 
compared to the natural compound (UDP-Gal). Accordingly, incorporation of the stable isotope 15N 
in GlcNAc causes a one-unit mass difference in compound 3 when compared to the non-labeled UDP-
GlcNAc. 
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Scheme 1. Repetitive batch synthesis for (A) isotope-labeled UDP-[15N]GlcNAc (3) by the N-
acetylhexosamine-1-kinase (NahK), UDP-GlcNAc pyrophosphorylase (AGX1), and an inorganic 
pyrophosphatase (PPiase) and (B) isotope-enriched UDP-[13C6]Gal (6) by galactokinase (EcGalK), the 
UDP-sugar pyrophosphorylase from Hordeum vulgare (HvUSP) and PPiase. 
The direct salvage enzyme cascades utilized in this study are characterized in previous works 
by great space-time yields and high stability under optimized reaction conditions [23,38,39]. 
Additionally, their application into a repetitive batch approach maximizes the enzyme productivities 
and reduces, therefore, enzyme preparation time and effort to the minimum (Supplementary 
Materials, Table S1). As demonstrated in previous studies for the synthesis of a set of non-labeled 
nucleotide sugars, this synthesis approach is highly reproducible and can be easily scaled up to a 
multi-gram scale without extensive laboratory effort [39]. Due to a complete conversion, unreacted 
sugars and intermediates were not present, while nucleotides can be straightforwardly degraded, 
using an alkaline phosphate. As previously demonstrated, obtained nucleotide sugar solutions are 
ready to use for a subsequent Leloir-glycosyltransferases-mediated glycan synthesis [32]. 
Table 1. Analysis of the synthesized nucleotide sugars compounds 3 and 6 by capillary 
electrophoresis with UV detection (CE-UV) and electrospray ionization mass spectrometry (ESI-MS). 
Compound Amount 
[µmol] 
Average Yield 
[%] 
Calculated 
m/z [M − H]− 
Observed 
m/z [M − H]− 
3 (UDP-[15N]GlcNAc) 200 100% 607.1 a) 607.2 
6 (UDP-[13C6]Gal) 400 100% 571.3 a) 570.9 
UDP-GlcNAc a)   606.1 606.2 
UDP-Gal a)   565.3 a) 564.9 
a) Provided from our previous study [39]. 
2.2. HMOS Synthesis 
The synthesized nucleotide sugars were used without any further purification step in a 
sequential synthesis of 13C6-labeled and non-labeled linear HMOS with type I or type II LacNAc 
extensions of the lactose core as depicted in Scheme 2. The respective reaction progress was 
monitored by capillary electrophoresis with laser-induced fluorescence detection (CE-LIF). Suitable 
internal standards for migration time alignment allowed for product assignment including the 
challenging linkage isomers (Supplementary Materials, Figures S1–S5). 
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Scheme 2. Sequential enzymatic synthesis of human milk oligosaccharides (HOMS). Compounds 10, 
12, 14, 16, 18, 20, 22, and 24 contain 13C6-enriched galactoses in each LacNAc unit. Compounds 8, 9, 
11, 13, 15, 17, 19, 21, and 23 were synthesized as unlabeled HMOS. 
Product characterization and determination of relative conversion rates were carried out using 
more sensitive, high-performance multiplexed capillary gel electrophoresis with laser-induced 
fluorescence detection (xCGE-LIF). xCGE-LIF has proven as an ideal separation tool for 
oligosaccharide analysis, enabling rapid separation and detection of isomeric compounds, even with 
small differences in the monosaccharide composition, positions, and linkages [16,41–46]. This 
technique can be employed in a multi-capillary format (up to 96 capillaries), making the method high-
throughput and thereby appropriate for enzyme reaction monitoring and product identification [47]. 
The normalized migration times of synthesized isotopically labeled HMOS were compared to the 
normalized migration times of commercial native HMOS standards if available (Figure 1). 
Identification and annotation of OS were carried out primarily based on our internal HMOS database 
(comparison of migration times). Identification and annotation of synthesized HMOS by comparison 
of migration times with in-house database entries (consisting of commercially available standards 
and previously annotated structures) was feasible for all synthesized structures since a wide range of 
linear HMOS, even the ones with minor structural differences, were extensively characterized and 
annotated previously [23]. Compositions of products were verified by LC-ESI-MS and MALDI-TOF-
MS (Supplementary Materials, Figures MS5–MS17 and MTS1–MTS7). 
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Figure 1. Multiplexed capillary gel electrophoresis with laser-induced fluorescence detection (xCGE-
LIF) analysis of the linear HMOS synthesis products: tetraoses (A), hexaoses (B), and octaoses (C). 
Upper electropherograms show (i) 13C6 galactose-enriched compounds 10, 14, 18, 20, 22, and 24 and 
(ii) centered native compounds 9, 13, 17, 19, 21, and 23. The bottom electropherograms display (iii) 
the migration time matching with commercially available standards. Lacto-N-neo-type HMOS were 
analyzed after 24 h reaction time, while the final reaction step for Lacto-N-type (terminal β3Gal) 
compounds was carried out after 72 h. Symbolic representation of oligosaccharide structures is drawn 
with GlycoWorkbench v.1.0.3353 by the guidelines of the Consortium for Functional Glycomics: blue 
circle, glucose; blue square, N-acetylglucosamine; yellow circle, galactose [48,49]. 
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Formation of the synthesis intermediates (GlcNAc-terminated structures) was pushed to a 
quantitative conversion respectively by the addition of fresh enzyme and elongation of the reaction 
time up to 72 h if necessary (Supplementary Materials, Figure S1). With respect to the known 
specificity, the production of Lacto-N-triose II (GlcNAc-β1,3-Gal-β1,4Glc) has to be considered 
critically. The β3GlcNAcT is known for good conversion of longer poly-LacNAc type II motives 
[30,32] but also for a bad acceptance of structures without N-acetyl group [23,50]. Nevertheless, we 
were able to reach 92.3% conversion of lactose within 48 h and nearly full conversion (99.7%) after 68 
h reaction time as exemplarily depicted in Figure S6 (Supplementary Materials). The N-
acetyllactosamine type II core (Galβ1-4GlcNAc) was synthesized by the β3GlcNAcT from Helicobacter 
pylori and the human β4GalT which are already known for a good substrate conversion in poly-
LacNAc syntheses [30]. 
Synthesis of Lacto-N-type HMOS (Galβ1-3GlcNAc) was carried out by the E.coli β3GalT (WbgO) 
as described previously [32]. The acceptor's structure differs from the known sugar structures 
occurring in the E.coli O55:H7 O-antigen repeating unit [33]. Here, the substrate acceptance could be 
one important reason why we were not able to push the enzymatic reaction to a quantitative 
conversion (Figure 1B,C). We assumed further an enzymatic limitation, especially for longer 
structures, which was also observed in the previously published sequential synthesis of poly-LacNAc 
type I [32]. Regarding the lacto-N-neo-type HMOS synthesis, we mainly achieved good conversions 
(Figure 1; Supplementary Materials, Figures MTS1–MTS5). Surprisingly, we obtained only a yield of 
73% within the last sequential synthesis step for compound 18 ([13C6]lacto-N-neo-octaose). On the 
contrary, we obtained nearly full conversion (99.5%) for the synthesis of compound 17 with nearly 
the same reaction conditions (Figure 1; Supplementary Materials, Figure MTS6). Therefore, we 
assumed no enzymatic or structural limitation in this synthesis step especially since no substrate 
length limitation for the used human β4GalT is known from the previous studies [30,32,51]. 
Therefore, we rated the enzymatic elongation toward longer HMOS as feasible, possibly after a clean-
up which removes reaction residues from earlier steps. Since the scope of this study focuses on a 
semi-sequential synthesis set-up without purification steps and we were not aiming for even longer 
structures, we did not investigate this further. 
The sequential synthesis of 13C6 and 15N-labeled lacto-N-neo-tetraose ([13C6/15N]LNnT) depicted 
in Scheme 3 delivers an overall synthetic yield (lactose-based) of 91.6% (Supplementary Materials, 
Figures S6 and MTS7 (purified compound 25)). Starting from the isotopically labeled 
monosaccharides [13C6]Gal and [15N]GlcNAc, the incorporation yield was calculated to be 74.2% 
overall synthetic steps. Hereby a slight excess of nucleotide sugars used for the transferases-mediated 
synthesis steps to [13C6/15N]LNnT affects the incorporation yield. Nevertheless, we rated the 
introduced synthesis strategy as a very efficient approach. In addition, we achieved the synthesis of 
[13C6/15N]LNnT in a multi-µmol scale (106 µmol). For its application as an internal standard in the 
quantification of milk OS, it was necessary to confirm that the compound was obtained in good 
quality, with no other milk OS in the sample that could compromise the purity and consequently 
quantification accuracy. Purity and identity of the isotopically enriched standard were confirmed by 
xCGE-LIF and MALDI-TOF-MS (Supplementary Materials, Figure MTS7). We observed the desired 
compound only and no lactose or triose after purification by an ultra-dialysis step. Additionally, to 
determine the number of OS, it was necessary that the standard used is quantitative. Therefore, an 
aliquot of the synthesized and purified [13C6/15N]LNnT isotope-standard solution was estimated by 
total organic carbon (TOC) analysis (Supplementary Materials, Figure TOCS1, and Table TOCS1). 
Data obtained enabled us to apply the compound as a quantitative standard for a proof-of-concept 
exercise showing the potential utility of enzymatically synthesized standards for quantification of 
HMOS, even in a complex matrix like milk. 
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Scheme 3. Sequential enzymatic synthesis cascade for 13C6 and 15N-labeled Lacto-N-neo-type tetraose 
(compound 25). (A) Synthesis of Lacto-N-triose II using previously synthesized UDP-[15N]GlcNAc as 
a substrate. (B) Synthesis of [13C6/15N]LNnT, [13C6]Gal(β1,4)[15N]GlcNAc(β1,3)Gal(β1,4)Glc using 
previously synthesized UDP-[13C6]Gal. 
2.3. Absolute Compound Quantification in Complex Samples by MS 
There is an increasing amount of reports showing that biological functions of HMOS depend not 
only on the specific structure of an HMOS but also on the quantity of the HMOS [52–56]. Therefore, 
in order to better understand all the effects of HMOS on infant health and risk of diseases, it is 
important to be able to quantify these compounds. Accurate, sensitive, fast, and straightforward 
methods that can quantify these compounds even in complex matrixes ranging from body fluids to 
food formulas will be essential for future studies. 
Besides chromatography (e.g., high-performance liquid chromatography with UV or 
fluorescence detection and high-pH anion-exchange chromatography with pulsed amperometric 
detection) [57–66] and electrophoresis (e.g., CE-UV and CGE-LIF) [16,67–70], MS has emerged as one 
of the methods of choice for the elucidation and characterization of milk OS from various sources 
because of its high resolving power, specificity, and selectivity, which is the result of differentiation 
of compound based on specific masses and from the fragmentation specific to linkage and 
monosaccharide sequence [15,71–74]. MALDI-MS has become a fast, simple, and convenient method 
for the analysis of even complex HMOS mixtures [75–77]. However, studies on the analysis of HMOS 
using MALDI-MS have been mainly qualitative as the absolute quantification is compromised by 
structure-dependent ionization efficiencies, ion suppression in complex samples, fluctuations in 
instrument performance, and variability in matrix crystallization. These sources of variability in 
MALDI-TOF-MS can be greatly diminished by the use of stable isotope-labeled standards. Briefly, 
due to the introduced mass difference, there is no overlap in the spectra between native and stable 
isotopes-labeled analytes. Both the analyte and its isotopic pair have equal ionization efficiency so 
that, when spiked to the analyte-containing sample in a known concentration, the isotope-labeled 
internal standard acts as a molecular balance. Given that the molar ratio of the isotopologues is within 
the linear range of the so-called response factor, one can easily compare their signal intensity or area 
under the curve (AUC) and deduce absolute quantities. Absolute quantification by MS employing 
stable isotope-labeled internal standards has been a routine method in metabolomics and proteomics 
and is recently introduced for quantification of another group of complex OS—N-glycans [17,78–82]. 
In contrast, quantification of milk OS by MS has been hampered largely by a lack of isotope-labeled 
HMOS standards. This study aimed to overcome this issue by an enzymatic synthesis of isotope-
labeled HMOS. 
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As one example for the use of these enzymatically synthesized heavy isotope-labeled HMOS 
standards, we applied [13C6/15N]LNnT for the MALDI-TOF-MS-based absolute quantification of 
commercial LNnT spiked into homogenized bovine milk. In comparison to human milk, bovine milk 
contains qualitatively and quantitatively fewer OS (25 identified of the 39 reported) [83,84]. 
Nevertheless, it was essential to prove that there was no detectable tetraose in commercial bovine 
milk used as a matrix to be spiked with commercial and synthesized isotope-labeled LNnT. 
(Supplementary Materials, Figure MTS8). The 7 Da mass increment of [13C6/15N]LNnT over the native 
compound LNnT facilitated a clear separation of the isotopic profiles, which was a necessary 
prerequisite for an accurate quantification (Supplementary Materials, Figure MTS9). To evaluate the 
response factor and dynamic range of the MALDI-TOF-MS analysis, LNnT and [13C6/15N]LNnT were 
analyzed with varying molarities (Figure 2(A)). The coefficient of determination (R2) of 0.999 confirms 
the linear response for relative molarities of LNnT to [13C6/15N]LNnT from 0.1 to 10. Furthermore, the 
response factor and dynamic range were investigated taking into account the complete sample 
preparation workflow (Figure 2(B)). The linear regression (R2 = 0.998) for samples extracted from 
bovine milk is in great accordance with the direct analysis of LNnT and [13C6/15N]LNnT. The data 
indicates no negative effect of the sample preparation for absolute quantification. 
 
Figure 2. Calibration plots for the response function of LNnT to [13C6/15N]LNnT by matrix-assisted 
laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS). [13C6/15N]LNnT was 
mixed commercial LNnT in H2O (A) and bovine H-milk (B), covering a broad spectrum of 
concentrations (0.25 µM to 1.5 mM). The graph displays averaged replicates with error bars 
representing the standard deviation (n > 3). LNnT and [13C6/15N]LNnT were purified from bovine H-
milk (Weinstephan, 3.5% fat) by porous graphitized carbon-solid-phase extraction (PGC-SPE). 
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In order to challenge the method in a more complex matrix, we used [13C6/15N]LNnT as an 
internal standard for the quantification of tetraose in a human milk sample, collected 153 days 
postpartum. As complexity and oligosaccharide content of human milk far exceeds the one from 
bovine milk, with some reporting at least 1000 different OS in human milk [77], it was necessary to 
examine that there were no compounds interfering with the quantification. Therefore, OS extracted 
from the human milk sample were analyzed without the addition of the isotope-labeled standard 
(Figure 3(A)). The zoom into the m/z range from 726 to 746 (Figure 3(A-ii)) shows not only the 
expected isotopic distribution of tetraose (monoisotopic peak indicated by an asterisk) [85] but also 
an otherwise flat baseline. These findings approve the eligibility of [13C6/15N]LNnT as an internal 
standard for MALDI-TOF-MS-based quantification of tetraose in human milk. In an analogous 
manner to the aforementioned results, different quantities of human milk (0.25 to 3 µL) were diluted 
in H2O and spiked with 1 µL [13C6/15N]LNnT (1 mM). A representative measurement is depicted in 
Figures 3(B-iii) and 3(B-iv), showing human milk-derived tetraose (m/z of 730.6 [M + Na]+) and the 
enzymatically synthesized standard (m/z of 737.6 [M + Na]+) with a mass difference of 7 Da (based on 
singly charged species). The early incorporation of the internal standard into the human milk sample 
resulted in improved reproducibility and robustness of the quantification, due to the identical 
treatment of target compound and standard. This advantageous feature was confirmed by the linear 
response function (R2 = 0.9927) of tetraose and [13C6/15N]LNnT, extracted from human milk 
(Supplementary Materials, Figure S7). Based on linear regression, a tetraose concentration of 1.33 mM 
was determined for the human milk sample (153 days postpartum). The exemplarily shown 
utilization of 1 µL internal standard (1 mM) enables the precise quantification of tetraose from human 
milk over a relative concentration range of more than 1 order of magnitude (application of 0.25 to 3 
µL human milk). Therefore, the enzymatically tailored HMOS evade the need for time- and labor-
intensive preliminary experiments to find adequate standard concentrations for different sample sets. 
Nevertheless, the applied MALDI-TOF-MS-based method has some drawbacks, like the inability 
to distinguish the linkage isomers lacto-N-tetraose (LNT) and LNnT, both present in human milk 
[2,6]. While there are techniques like the analysis of post-source decay fragment ions and instruments 
such as ion-mobility MS, which are facilitating additional resolution, these approaches demand not 
only appropriate equipment but also certain expertise. However, the use of isotope-labeled standards 
while incorporating a high-resolution separation step prior to MS should increase information gained 
and improves the quantification process by separating various isomers that cannot be differentiated 
by mass alone. 
Results obtained by different groups analyzing concentrations of LNnT and LNT reported in 
human milk vary considerably. Such variation may be attributed to the general biological variability 
as well as to other biological parameters like gestational age, Lewis blood group, secretor status of 
the mother, lactation period, or analytical methods [8,86]. All this variability makes it difficult to 
compare the presented results with other studies. LNT and LNnT are naturally occurring 
tetrasaccharides belonging to the group of non-fucosylated neutral HMOS. It was shown that they 
could protect against important systemic infections of the newborn [9,87–89]. In addition, they act as 
natural prebiotics, promoting the growth of beneficial gut microbiota (bifidobacteria and lactobacilli), 
thereby suppressing the growth of undesirable bacteria [90–93]. LNnT is, besides 2´-fucosyllactose 
(2′-FL), the only synthetically produced oligosaccharide approved by the European Food Safety 
Authority (EFSA) for supplementation to infant formula [12]. For these reasons, a fast, accurate, and 
sensitive method that can quantify these OS will be very useful for future studies. 
Another reported approach which is taking advantage of the mass difference between the light 
and heavy form of an oligosaccharide is based on the incorporation of stable isotopes into OS by 
reductive amination [18,94,95]. One sample is reduced with sodium borohydride, and another is 
decreased with sodium borodeuteride, and afterward, two samples are mixed in a 1:1 (v/v) ratio. The 
ratios of light and heavy isotope-labeled OS are then used to compare the relative intensities between 
the two samples. Limitation of this approach is that only the relative quantification is achieved and, 
due to overlapping isotopic signals of unlabeled and labeled OS, analysis becomes more difficult. 
With the availability of isotopically labeled HMOS standards, the MALDI-TOF-MS-based approach 
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can position itself as a fast, simple, sensitive, and precise tool for HMOS quantification, even in a 
complex sample. 
 
Figure 3. (A) MALDI-TOF mass spectrum of PGC-SPE extracted human milk in the m/z range from 
300 to 2500 (i) and the magnified m/z range from 726 to 746 (ii). An asterisk indicates the signal 
corresponding to tetraose (m/z = 730.6204 [M + Na]+). (B) MALDI-TOF mass spectrum from PGC-SPE 
extracted human milk spiked with [13C6/15N]LNnT. An asterisk in the in the m/z range from 300 to 
2500 (iii) indicates the signals corresponding to tetraose (m/z = 730.6204 [M + Na]+ and [13C6/15N] LNnT 
(737.641 [M + Na]+). The two isotopologues are highlighted in the amplified m/z range from 726 to 
746 (iv). 
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3. Materials and Methods 
3.1. Recombinant Enzyme Preparation 
Expression and subsequent purification of the recombinant transferases: the human β1,4-
galactosyltransferase-1 (β4GalT), the E.coli O55:H7 β1,3-galactosyltransferase (β3GalT), and a the 
β1,3-N-acetylglucosaminyltransferases from Heliobacter pylori (β3GlcNAcT) were carried out as 
described previously [23,27,29,30,32]. For the β3GalT and the β3GlcNAcT, a buffer exchange was 
carried out by dialysis (10 kDa cut-off). The β3GalT dialysis buffer contained 100 mM NaH2PO4 at 
pH 7.5, 500 mM NaCl, and 5 mM DTT. The β3GlcNAcT dialysis buffer consisted of 20 mM Tris-HCl 
at pH 7.4, 200 mM NaCl, 1 mM EDTA and 1 mM DTT. The purified enzymes were stored at 4 °C. 
Heterologous kinases and pyrophosphorylases expression, as well as purification, were done as 
published before [37–39]. EcGalK, HvUSP, NahK, and the human AGX1 were subsequently 
diafiltrated and concentrated in a 30 kDa centrifugal concentrator (Vivaspin® 20) from Sartorius 
(Göttingen). Therefore, a 50 mM Tris/HCl buffer (pH 7.5) was used. EcGalK and AGX1 were stored 
at −20 °C, and β4GalT, β3GalT, β3GlcNAcT, NahK, and HvUSP were stored at 4°C after the buffer 
exchange. 
3.2. Enzyme Activity Assay 
Kinases and pyrophosphorylases activity tests were carried out in a 96-well plate format on a 
multiplexed capillary electrophoresis system with UV detection (MP-CE (UV)) as described before 
[37–39]. Briefly, the reactions were carried out in a volume of 300 µL and at 37 °C. The reaction 
mixture for NahK contained 1 U pyrophosphatase from Saccharomyces cerevisiae (Sigma-Aldrich 
(Roche)), 2 mM GlcNAc, 2 mM ATP, and 2 mM MgCl2 and was buffered by 50 mM Tris(HCl) at pH 
8.0. The AGX1 reaction mixture was also buffered by a Tris(HCl) system (pH 8.0) and supplemented 
with 2 mM GlcNAc-1-P, 2 mM MgCl2, 2 mM UTP, and 1 U pyrophosphatase. For the EcGalK reaction 
mixture, 2 mM Gal, 2 mM MgCl2, 2 mM ATP, and 1 U pyrophosphatase were buffered at pH 7.5 by 
50 mM Tris(HCl), while the HvUSP mixture contained 1 U pyrophosphatase, 2mM Gal-1-P, 2 mM 
MgCl2, and 2 mM UTP in a 50 mM Tris(HCl) buffer system (pH 7.5). The reactions were stopped at 
different time points by the addition of a termination solution, containing sodium dodecyl sulfate 
(SDS), to a final concentration of 7 mM to denature the enzymes immediately. Internal normalization 
standards, 4-aminobenzoic acid (PABA) and 4-aminophthalic acid (PAPA), were added to the sample 
solution together with the termination solution to a final concentration of 1 mM, respectively. The 
peak areas were normalized to PABA, and the concentrations were determined via calibration curves 
as formerly published [37–39]. Kinases activities were determined by increasing ADP concentrations. 
While the pyrophosphorylases activities were determined by the UDP-sugar increase over time. The 
quantification of these UV-active compounds was carried out as formerly described by Wahl et al. at 
a wavelength of 254 nm [37]. More precisely, a calibration curve was recorded for the peak area of 
commercial standards normalized to the peak area of 1 mM para-amino benzoic acid (PABA) plotted 
against the varying standard concentration. Analytes concentrations were deduced from the linear 
slope area, calculated with the obtained normalized peak area. Therefore, one µmol substrate 
conversion per minute was defined as 1 U (enzyme unit). 
Transferases activity assays were carried out and analyzed on CE-LIF as described previously 
[23]. Shortly, all reaction mixtures were incubated at 30 °C and contained 6.5 mM MnCl2, 6.5 mM 
MgCl2 as well as 6 U alkaline phosphatase (AP) (ThermoFischer) buffered by 100 mM Tris(HCl) at 
pH 7.5. Each 5 mM of the respective acceptor substrate, 6.5 mM of the respective nucleotide sugar, 
and 10 µg purified enzyme were supplemented to start the reactions. More precisely, lactose and 
UDP-GlcNAc were used for the β3GlcNAcT assay, and Lacto-N-triaose and UDP-Gal were used for 
the β4GalT and β3GalT assays. The enzyme reactions were stopped by heating up small samples (6 
µL, 95 °C for 5 min) on different time points. After centrifugation, the supernatant (2 µL) was used 
for fluorescent labeling (8-aminopyrene-1,3,6-trisulfonic acid (APTS)), post-derivatization 
hydrophilic interaction chromatography-solid phase extraction (HILIC-SPE) sample clean-up and 
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analysis via CE-LIF as described in the Method section and previous studies [23,43]. The volumetric 
activity (U/mL) was calculated from the linear slope area. 
3.3. HMOS Analysis via CE-LIF and xCGE-LIF 
CE-LIF was mainly used to determine the transferases activity, as described above, and follow 
the HMOS synthesis reaction. APTS labeling, HILIC-SPE clean-up, and CE-LIF measurement were 
carried out as described before [23,43]. Additionally, commercial maltose, cellooctaoses, and 
maltononaoses were spiked as internal migration time normalization standards. High-resolution and 
-sensitivity xCGE-LIF analytics were used for a structure verification based on a migration time 
matching to the in-house database and commercially available standards [39]. Sample preparation 
including APTS labeling, HILIC-SPE, and further xCGE-LIF measurement and analysis was carried 
out as detailed described before [42,43]. 
3.4. Nucleotide Sugar Synthesis 
UDP-[13C6]galalactose and UDP-N-acetyl-[15N]glucosamine were produced as published before 
in a repetitive batch mode using a centrifugal concentrator device (Vivaspin®) as a reactor and 
separation device [39]. For the synthesis, commercially available isotopically labeled 
monosaccharides (Sigma/Campo and Omicron Biochemicals) were used. To receive an optimal 
conversion, all reaction solutions were pre-tempered, and the synthesis reaction time was elongated 
to each one h in total. The concentration was determined as described before by MP-CE (UV) analysis 
[37–39]. Briefly, the product concentrations were determined by the peak area normalized to the 
internal standard PABA and calculated using a calibration curve of the corresponding commercial 
non-isotope-labeled nucleotide sugars. 
3.5. Sequential 13C6 and Native HMOS Synthesis 
For the sequential synthesis of compound 8, the initial reaction mixture was buffered by 100 mM 
Tris/HCl (pH 7.5). The mixture contains further 25 mM KCl, 1 mM MgCl2, 1 mM MnCl2, 1 mM lactose 
(compound 7), 1 mM in-house produced UDP-GlcNAc, and 20 mU/mL AP. β3GlcNAcT (50 mU/mL) 
was  added to start the reaction in a total volume of 2 mL, respectively. The reaction was incubated 
at 30 °C for at least 24 h. The product formation was monitored by CE-LIF as described in the 
corresponding section. If necessary, the reaction time was elongated to 72 h and fresh enzyme and 
nucleotide sugar were supplemented after 24 h. Removal of the enzymes between the sequential steps 
was carried out by an ultra-filtration step using a centrifugal concentrator as recommended by the 
supplier (Vivaspin®500 from Sartorius, 10 kDa). Ongoing sequential product elongation with 
constant buffer and compound compositions (mentioned above) was started by the addition of AP, 
the respective transferase (250 mU/mL β4GalT, 150 mU/mL, β3GalT mU/mL, or 50 mU/mL 
β3GlcNAcT) and the respective in-house produced nucleotide sugar. Defined lengths of HMOS 
(target compounds 10, 14, 18, 20, 22, 24 and 9, 13, 17, 19, 21, 23) were synthesized by alternating 
addition and removal of the transferases β3GlcNAcT, β4GalT, or β3GalT and the respective in-house 
synthesized nucleotide sugar starting from lactose. The progress of each enzymatic elongation step 
was monitored by CE-LIF and additional structural characterization was performed by xCGE-LIF, 
LC-ESI-MS, and MALDI-TOF-MS, as described elsewhere in this paper. 
3.6. Sequential Synthesis of 13C6 and 15N-Labeled Lacto-N-Neo-Tetraose 
Synthesis of 13C6 and 15N-labeled LNnT (compound 25, [13C6]Gal-β1,4-[15N]GlcNAc- β-1,3-Gal-β-
1,4-Glc) was carried out on a 125 µmol scale. The reaction contained 6.25 mM MgCl2, 25 mM KCl, 5.5 
mM pre-synthesized UDP-[15N]GlcNAc, 5 mM lactose, and 1 mM DTT in a Tris/HCl buffer system 
(pH 7.5). Addition of 100 mU/mL β3GlcNAcT and 20 mU/mL AP started the reaction. After 48 h at 
30 °C, the intermediate formation was monitored by CE-LIF as described in the corresponding 
section, which took additional 20 h (labeling, clean-up, and measurement). Afterward, the reaction 
was stopped by heat inactivation of the involved enzymes for 5 minutes at 95 °C. Further elongation 
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was carried out by the addition of 6.25 mM MgCl2, 250 mU/mL β4GalT, 20 mU/mL AP, and 5.5 mM 
pre-synthesized UDP-[13C6]Gal. The reaction was stopped by a heat-inactivation step (5 min/95 °C) 
after an additional 48 h incubation at 30°C and the final product formation was analyzed by CE-LIF. 
The [13C6/15N]LNnT was pre-treated for further experiments by ultra-dialysis. Briefly, enzymes were 
removed after heat precipitation by centrifugation. Low-molecular-synthesis compounds were 
removed by at least 3 times low-cut-off (100–500 Da, FloatALyser® G2) dialysis against ultrapure 
water overnight monitored by a conductivity meter. The samples were dried in a vacuum 
concentrator at 60 °C overnight and resolved in ultrapure MilliQ water. 
3.7. TOC Analysis of the Purified [13C6/15N]Lacto-N-Neo-Tetraose 
The organic carbon content of the samples was determined by a Sievers M9 TOC Analyzer (GE 
Analytical Instruments, Manchester, United Kingdom) by measuring the difference between the total 
carbon (TC) and the total inorganic carbon (TIC). TC of the sample was wet-chemical oxidized with 
UV radiation forming CO2 which passed a CO2 permeable membrane for detection by 
conductometry. TIC was reacted to CO2 using phosphoric acid and passed the same CO2-permeable 
membrane for detection by conductometry. The TOC value was given by the difference between 
these two values: TOC = TC – TIC. The measurement was conducted at a sample flow of 0.5 mL/min 
while adding 1 µL/min phosphoric acid (6 M) and 2.8 µL/min ammonium persulfate solution (15% 
w/w) for a working range up to 50 ppm TIC and 10 ppm TOC. The detection range was specified by 
the manufacturer from 0.03 ppb to 50 ppm with a precision of ±2%. The initial calibration was done 
with potassium hydrogen phthalate (Merck KGaA, Darmstadt, Germany, 1.09017.0100) and was 
linear in a range from carbon-free samples up to 10 ppm organic carbon. Of the samples, 1 mg was 
weighed with a Mettler AT 261 Delta range balance (±0.02 mg accuracy) and dissolved in 10 mL 
ultrapure water. These solutions were diluted 10 and 20 times with ultrapure water and measured 
against the same ultrapure water as blank. For validation of the method, the carbon content of α-
Lactose Monohydrate (Merck KGaA, Darmstadt, Germany) was calculated by measuring the 
corresponding TOC and dividing it by the initial sample weight. The agreement between the 
experimental value (39.67% w/w) and the theoretical value (39.97% w/w) shows the high accuracy of 
the method. 
3.8. MS-Based Analysis 
All experiments, including sample preparation steps for MS measurements, were carried out 
using LC-MS-grade water and chemicals if not stated otherwise. Qualitative characterization of the 
synthesized HMOS standards was carried out as described previously [23]. All enzymatically 
synthesized HMOS samples were prepared for MS analysis by ultra-dialysis as detailed described 
above for the [13C6/15N]LNnT pre-treatment. 
3.9. Nucleotide Sugar and HMOS Analysis via ESI-MS 
Mass verification of the nucleotide sugars in pre-treated samples was carried out as described 
previously [39]. Briefly, the remaining reaction residuals (nucleoside phosphates) were removed 
from the samples by an AP digest overnight at room temperature. Afterward, the enzymes were 
removed by an ultra-flirtation step using a centrifugal concentrator as recommended by the supplier 
(Vivaspin®500 from Sartorius, 10 kDa). Flow-through samples of prepared compounds 1–4 were 
partly supplemented with 0.1–0.5 µL ammonium hydroxide. Their subsequent analysis was 
performed on a Dionex HPLC system equipped with a Multospher 120 RP 18 HP-3µ HPLC column 
(60 mm × 2 mm) from CS-Chromatographie Service GmbH, Langerwehe. Therefore, an MS-grade 
ACN/water (50:50, v/v) mixture was used as a mobile phase with a flow rate of 0.2 mL min−1. Mass 
data were collected with a connected ESI-MS detector (Finnigan Surveyor MSQ Plus from Thermo 
Scientific) in a negative mode. The temperature was set to 400 °C, the needle voltage was set to −4 kV, 
and the cone voltage was set to 100 V. 
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The samples were supplemented with small amounts (0.1–0.5 µL) of ammonium hydroxide. 
Afterward, HMOS mass was analyzed using an LC-ESI-MS system. Therefore, a Dionex system was 
equipped with a polymer-based HILIC column (Shodex Asahipak NH2-50 4E (4.6 × 250 millimeter 
(mm))). As a mobile phase, an ACN:water gradient from 70% to 50% ACN over 15 minutes followed 
by an additional 5 minutes with an isocratic flow at 50% ACN (1 mL/min) was used. Mass data were 
collected using the conditions and the connected ESI-MS detector mentioned above for the nucleotide 
sugar analysis. All experiments for MS analysis were carried out with ultrapure water and LC-MS-
grade ACN. 
3.10. Extraction of OS from Human Milk 
The human milk sample was collected 153 days postpartum using a manual milk pump and 
immediately stored at −20 °C. OS were isolated from human and bovine milk-based on a modified 
version of a previously reported workflow [75]. Therefore, 0.25 to 3 µL of human milk was diluted to 
49 µL with H2O and spiked with 1 µL [13C6/15N]LNnT (1 mM). Bovine milk (10 µL 3.5% fat H-milk 
from Weihenstephan diluted to a final volume of 100 µL) was spiked with 1 µL [13C6/15N]LNnT (1 
mM) and 0.1 to 10 µL commercial LNnT (1 mM) (Elicityl, Crolles, France). All samples were 
centrifuged at 14,000× g and at room temperature for 20 min using a Heraeus Fresco 17 
microcentrifuge (Thermo Scientific, Bellefonte PA, USA). Subsequently, 60% of the aqueous phase 
was subjected to solid-phase extraction (SPE). For each sample, approximately 2 mg porous graphitic 
carbon (PGC) from prepacked 25 mg cartridges (Thermo Scientific, Bellefonte PA, USA) were loaded 
onto Pierce C18 100 µL tips (Thermo Scientific, Bellefonte PA, USA), placed in a 96-well PCR rack. To 
pass the liquid through the stationary phase, the rack was placed on a 96-deep well storage plate and 
centrifuged at 500× g and at room temperature for 1 min using a Heraeus Multifuge X1R (Thermo 
Scientific, Bellefonte PA, USA). 
Equilibration of the stationary phase was achieved in two cycles of sequential application of 100 
µL 40% (v/v) ACNaq and 100 µL 20% (v/v) ACNaq (both 0.1% (v/v) TFAaq), followed by 100 µL 0.1% 
(v/v) TFAaq five times. After the application of approximately 60 µl sample, the PGC material was 
washed five times with 100 µL 0.1% (v/v) TFAaq. Following elution in 70 µL 40% (v/v) ACNaq 
containing 0.1% (v/v) TFAaq three times, all samples were dried for MALDI-TOF-MS analysis using a 
FRVC 2-33 CDplus rotational vacuum evaporator (Martin Christ, Osterode am Harz, Germany) and 
resolubilized in 10 µL H2O (extraction from human milk) or 20 µL H2O (extraction from bovine milk). 
3.11. MALDI-TOF-MS Analysis and Absolute Quantification of HMOS 
All MALDI-TOF mass spectra were acquired on an ultrafleXtreme MALDI-TOF/TOF-MS 
(Bruker Daltonics, Bremen, Germany) in reflectron positive ion mode. For each spectrum, 15,000 laser 
shots (50 shots per raster point in random walk) from a Smartbeam-II laser were averaged using a 
120 ns delayed extraction time and a 25 kV accelerating voltage. For external calibration of the m/z 
range from 200 to 2500, a peptide standard mixture (Bruker Daltonics) and a dextran hydrolysate 
were used. Analyte ionization was facilitated by freshly prepared super-dihydroxybenzoic acid (S-
DHB) (≥99.0%, Sigma-Aldrich, Steinheim, Germany) matrix (10 mg/mL) in 30% (v/v) ACNaq, 0.1% 
(v/v) TFAaq, and 4 mM NaCl. Therefore, 0.5 µL matrix solution was spotted onto an MTP AnchorChip 
800/384 TF MALDI target (Bruker Daltonics) and immediately dried in a vacuum evaporator, 
followed by 0.5 µL sample spotted onto the matrix layer in an analogous manner. 
All spectra were processed with flexAnalysis version 3.3 Build 80 (Bruker Daltonics), using the 
top-hat filter for baseline subtraction and a centroid algorithm for peak detection with 0.5 m/z peak 
width and a signal-to-noise ratio (SNR) threshold of 6. Processed spectra were exported in text format 
and transferred to OriginLab 2019 and Microsoft Excel for data evaluation. To determine the methods 
dynamic range and verify the direct proportionality of monoisotopic peak intensities from LNnT (m/z 
730.6204 [M + Na]+) and [13C6/15N]LNnT (m/z 737.641 [M + Na]+), three calibration curves were 
prepared (one for each of the PGC-extracted samples (human and bovine milk) and one from a 
dilution series of synthesized [13C6/15N]LNnT with the commercial LNnT standard. 
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4. Conclusions 
To further deepen our understanding of the functions of milk OS, it is essential to first increase 
our knowledge not only on the variety and complexity of these molecules in human milk but also on 
their quantities. The quantification of these structurally complex and diverse but still similar 
compounds is often limited by the small number of commercially available standards. Therefore, we 
strived to establish an approach to the enzymatic synthesis of stable isotope-labeled HMOS that can 
be employed as internal standards for quantitative analysis. We provided a straightforward synthesis 
strategy to isotopically labeled nucleotide sugars with high yields regarding the valuable 
monosaccharide substrates. Further, we introduced a flexible sequential synthesis approach to 
efficient tailoring of stable isotope [13C6]-labeled linear HMOS structures by the use of Leloir-
glycosyltransferases. We demonstrated synthetic capabilities as well as the potential and limitations 
of the introduced strategy for selected HMOS up to octaoses. We further presented for the first time 
the enzymatic synthesis of 15N-enriched UDP-[15N]GlcNAc and its precise incorporation in a 
[13C6/15N]Lacto-N-neo-tetraose in a 106 µmol scale with an overall percentage yield (lactose-based) of 
91.6%. Analysis of tetraose in complex milk mixtures was thought as a proof-of-concept exercise to 
show that MALDI-TOF-MS-based profiling method, when combined with well-defined 13C 
standards, can become a rapid, robust, and sensitive method for absolute quantification of milk OS. 
In conclusion, the presented synthesis approach enables increased access to an even broader set 
of enzymatically tailored isotope-labeled HMOS than here described. Neutral HMOS (with type I 
and II extensions) represent basic structural motifs of many known HMOS which are accessible for 
further modifications, e.g., fucosylation or sialylation. Additionally, the sequential set-up combined 
with a purification step allows for precise incorporation of an isotopic sugar unit on a freely selectable 
position according to the respective demand. Tailored isotopically labeled HMOS could not only 
enable fast and straightforward quantitative MALDI-TOF-MS-based analysis, but even allow 
quantifying challenging linkage isomers of neutral HMOS when separation precedes detection by 
MS. The use of stable isotope-labeled HMOS standards may help to gain more information about the 
concentrations of OS in human milk or any other biofluid such as feces and urine, a crucial step 
towards a deeper understanding of HMOS structure-function relations and implementation to infant 
nutrition. 
Abbreviations: 2´-fucosyllactose (2′-FL); 4-aminobenzoic acid (PABA); 4-aminophthalic acid (PAPA); 8-
aminopyrene-1,3,6-trisulfonic acid (APTS); alkaline phosphatase (AP); area under the curve (AUC); β1,3-
galactosyltransferase (β3GalT); β1,3-N-acetylglucosaminyltransferase (β3GlcNAcT); β1,4-galactosyltransferase-
1 (β4GalT); capillary electrophoresis with laser-induced fluorescence detection (CE-LIF); capillary 
electrophoresis with UV detection (CE-UV); electrospray ionization mass spectrometry (ESI-MS); European 
Food Safety Authority (EFSA); galactokinase (EcGalK); galactose (Gal); multiplexed capillary gel 
electrophoresis with laser-induced fluorescence detection (xCGE-LIF); lacto-N-tetraose (LNT); lacto-N-neo-
tetraose (LNnT); liquid chromatography–electrospray ionization–mass spectrometry (LC-ESI-MS); human milk 
oligosaccharides (HMOS); matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); 
matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS); 
oligosaccharides (OS); mass spectrometry (MS); multiplexed capillary electrophoresis system with UV detection 
(MP-CE (UV)); N-acetylglucosamine (GlcNAc); N-acetylhexosamine-1-kinase (NahK); N-acetyllactosamine 
(LacNAc); pyrophosphatase (PPiase); porous graphitized carbon-solid-phase extraction (PGC-SPE); 
pyrophosphate (PPi); signal-to-noise ratio (SNR); total carbon (TC); total inorganic carbon (TIC), total organic 
carbon (TOC); uridine-5´-diphospho-α-D-galactose (UDP-Gal); uridine-5´-diphospho-α-D-N-acetylglucosamine 
(UDP-GlcNAc); UDP-sugar pyrophosphorylase (AGX1); UDP-sugar pyrophosphorylase from Hordeum vulgare 
(HvUSP) 
Supplementary Materials: Additional CE-LIF electropherograms, as well as mass spectrograms, can be found 
in Supplementary Materials. Figures S1–S6 exemplarily depict the sequential synthesis progress and separation 
of challenging linkage isomers including the used internal migration time standards. Figures MS1–MS17 show 
ESI-MS mass spectrums of the synthesized products including nucleotide sugars and HMOS. Figures MTS1–
MTS6 show MALDI-TOF-MS mass spectrums of the synthesized HMOS. Figure MTS7 shows xCGE-LIF analysis 
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and MALDI-TOF-MS of the purified [13C6/15N]LNnT. Figure MTS7 shows the MALDI-TOF-MS mass spectrums 
of the complex sample matrix—bovine milk—before and after spiking of model analytes and the isotopic 
[13C6/15N]LNnT reference standard. Figure S7 shows the calibration plot for the response function to varying 
molar ratios of tetraose to [13C6/15N]LNnT in human milk. 
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